Ask AI
ProCE Banner Activity

RET in Oncogenesis and Evidence-Based Testing Strategies to Detect RET Fusions and Mutations

Slideset Download
Download these slides to review expert insights from a pathologist on best testing practices to identify patients with advanced thyroid cancer and NSCLC eligible for treatment with a RET specific inhibitor.

Released: March 16, 2021

Expiration: March 15, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology and Director of Molecular Oncology
Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine
Lebanon, New Hampshire